1. Abi-Dargham, Laruell M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. Neuropsychiatr Clin Neurosci 1997;9:1-17.

2. Abel KM, Keaney U, Murray RM. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br J Psychiatry 1996; 168;57-60.

3. Abraham HD, Aldridge AM., Gorgia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996; 14:285-298.

4. Ahlenuis S. Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 1989; 64:3-5.

5. Arora RC, Meltzer HY. Serotonin2 (5HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 1991;85:19-29.

6. Arora RC, Meltzer HY. Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Res 1993;47:111-119.

7. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5 HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217:177-178.

8. Beasley CM, Toleson G, Tran P, Satterlee W, Sanger T, Hamilton S. The Olanzapine HGAD Study Group; Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123.

9. Bleich A., Brown SL, Kahn R., van Praag HM. The role of serotonin in schizophrenia. Schizophr Bull 1988;14:297-315.

10. Braunig P, Rao ML, Flimmers R. Blood serotonin levels in suicidal schizophrenic patients. Acta Psychiatr Scand 1989;79:186–189.

11. Breier A. Serotonin, Schizophrenia and antipsychotic drug action. Schizophr Res 1995; 14:187-202.

12. Brody D, Adler LA, Kuo T, Aubust B, Rotrosen J. Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol 1990;10:68–69.

13. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15:442-55.

14. Chouinard G, Jones B, Ronnington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.

15. Collu M., Poggiu A.S. Devoto P., Serra G. Behavioral sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. Eur J Pharmacol 1997; 322:123-127.

16. Cooper SJ, Kelly CB, King DJ. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet 1992;340:940–941.

17. Costall B, Naylor R, Marsden C, et al. Serotoninergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol 1976;28:523-526.

18. Csernansky JG, King RJ, Faustman WO, Moses JA, Poscher ME, Faull KF. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. Br J Psychiatr 1990;156:501–507.

19. Dean B, Opeskin K, Pavey G, et al. [3H] Parozetine binding is altered in hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem 1995;64:1197-1202.

20. Elkis H, Friedman L, Wise A, Meltzer HY. Meta-analyses of studies of ventricular enlargement or cortical sulcal prominence in mood disorders-comparison to controls or patients with schizophrenia. Arch Gen Psychiatry 1995;52:735-746.

21. Erdman J, Shimron-Abarbanell D, Rietschel M, et al. Systematic screening for mutations in the human serotonin-2A 5-HT2 receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996; 97:614-619.

22. Farde L, Nordström A-L, Nyberg S, Hallden C. D1, D2 and 5-HT2 occupancy in clozapine treated patients. J Clin Pharmacol 1994;55 (Suppl B):9.

23. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emmission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15:19S-23S.

24. Ferre S, Cortes R, Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway; microdialysis studies in freely moving rats. J Neurosci 1994;14:4839-4846.

25. Gaddum JH, Hameed KA. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol 1954;9:240–248.

26. Garlow S, Morilak D, Dean RS, Roth BL, Ciaranello RD. Production and characterization of an antibody for the 5-HT2 receptor which labels a subpopulation of rat forebrain neurons. Brain Res 1993;615:113–120.

27. Gelders Y, Bussche GV, Reyntijens A, Janssen JAP. Serotonin S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 1986;9:325-327.

28. Gerlach J, Koppelhus P, Helweg E, Manrad A. Clozapine and haloperidol in a single-blind cross-over trial. Therapeutic and biochemical aspects in the treatment of schizophrenia: preliminary results from a double-blind study. Acta Psychiatr Scand 1974;50:410-424.

29. Geyer M, Puerto A, Menkes D, et al. Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Res 1976;106:257-270.

30. Glennon RA. Do classical hallucinogens act as 5-HT2 agonists or antagonistss? Neuropsychopharmacology 1990;3:509–517.

31. Goff DC, Brotrian AW, Waites M, McCormack S. Trial of fluxetine added to neuroleptics for treatment resistant schizophrenic patients. Am J Psychiatry 1990; 14:492-493.

32. Goff DC, Midha KK, Ofra S-S, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995;117:417-423.

33. Goldstein JM, Litwin LC, Sutton EB, et al. Effects of ICI 169, 369, a selective serotonin2 antagonists, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 1989;249:673-680.

34. Goyer PF, Berridge MS, Morris ED, et al. PET measurements of neuoreceptor occupancy by typical and atypical neuropleptics. J Nucl Med 1996;37:1122-1127.

35. Grahame-Smith DG, Geaney DP, Schachter M, Elliott JM. Human platelet 5-hydroxytryptamine receptors: binding of [3H]-LSD. Effects of chronic neuroleptic and antidepressant drug administration. Experentia 1988;44:142–145.

36. Grenhoff J, Tung CS, Ugedo L, et al. Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 1990;66 (Suppl 1):29-33.

37. Hallmayer J, Kennedy JL, Wetterberg L, et al. Exclusion of linkage between the serotonin2 receptor and schizophrenia in a large Swedish kindred. Arch Gen Psychiatry 1992;49:216–219.

38. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT2A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991;48:355–363.

39. Hicks PB. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990;47:1609-1615.

40. Heimke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-281.

41. Hoyer D. Functional correlates to 5-HT1 recognition sites. J Recept Res 1988;8:59–81.

42. Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D. Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology 1993;112:S76–S84.

43. Inayama Y, Yoneda H, Sakai T, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67:103-105.

44. Iqbal N, Asnis GM, Kahn RS, Kay SR, van Praag HM. The mCPP challenge test in schizophrenia: hormonal and behavioral responses. Biol Psychiatry 1991;30:770–778.

45. Ishigaki T, Xie DW, Liu JC, et al. Intact 5-HT2A receptor exons and the adjoining intron regions in schizophrenia. Neuropsychopharmacology 1996;14:339-347.

46. Iyo M, Nishio M, Itoh T, et al. Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatry Res 1993;50:217-231.

47. Jackson D, Abercrombie O. In vivo neurochemical evaluation of striatal serotonergic hyperinnervation in rats depleted of dopamine at infancy. J Neurochem 1992;58:890–897.

48. Jacobs BL, Wise WD, Taylor KM. Differential behavioral and neurochemical effects following lesions of the dorsal or median raphe nuclei in rats. Brain Res 1974;79:353-361.

49. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8:315–336.

50. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C. Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology 1993; 112:S90–S94.

51. Kane J, Honigfield G, Singer J, Meltzer HY, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789–796.

52. Kapur S, Remington G. Serotonin-dopamine interactions and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476.

53. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990;253:803–811.

54. Kolakowska T, Cowen PJ, Murdock P. Endocrine responses to tryptophan infusion in schizophrenic patients treated with neuroleptics. Psychoneuroendocrinology 1987;12:193–202.

55. Krystal JH, Seibyl JP, Price LH, et al. m-Chlorophenylpiperazine (MCPP) effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatr 1993;50:624–635.

56. Launay JM, Bondoux D, Oset-Gasque MJ, et al. Increase of human platelet serotonin uptake by atypical histamine receptors. Am J Physiol 1994; 35:526-536.

57. Laruelle M, Abi-Dargham A, VanDyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182-1190.

58. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psych 1993;50:810–818.

59. Lee HS, Bastani B, Friedman L, Ramirez L, Meltzer HY. Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. Biol Psychiatry 1990;27:691-694.

60. Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1995;10:67-72.

61. Lemus CZ, Lieberman JA, Johns CA, et al. Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients. Biol Psychiatry 1991;29:691–694.

62. Lemus CZ, Lieberman JA, Johns CA, et al. CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia. Biol Psychiatry 1990;27:923–926.

63. Lerer B, Ran A, Blacker M, et al. Neuroendocrine responses in chronic schizophrenia. Evidence for a serotonergic dysfunction. Schiz Res 1988;1:405–410.

64. Lewine RR, Risch SC, Risby E, et al. Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. Am J Psychiatry 1991;148:1189–1194.

65. Lindström LH, Wieselgren IM, Klockhoff I, Svedberg A. Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients. Biol Psychiatry 1990;28:435–442.

66. Losonczy MF, Song IS, Mohs RS, et al. Correlates of lateral ventricular size in chronic schizophrenia II: biological measures. Am J Psychiatry 1986;143:1113–1118.

67. Maes M, Meltzer HY. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizpherenic patients and normal volunteers. Psychiatry Res 1996;64:147-169.

68. Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996;153:1092-1094.

69. Marshall BD, Glynn SM, Midha KK, et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 1989;9:110–115.

70. Masellis M, Patterson AD, Badri F, et al. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 1995;346:1108.

71. Masellis M, Patterson AD, Badri F, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenic patients. Neuropsychopharmacol. In press.

72. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18–S27.

73. Meltzer HY. Clozapine: clinical advantages and biological mechanisms. In: Schulz SC, Tamminga C, eds. Schizophrenia: a scientific focus. New York: Oxford University Press; 1989:302–309.

74. Meltzer HY, Fatemi SH. The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs. Serotonergic mechanisms. In: Antipsychotic treatment. Kane JM, Moller H-J, Awouters F, eds. New York: Marcel Dekker, 1996;77-107.

75. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson’s disease: a high potency effect of clozapine. Neuropsychopharmacol 1995;12:39-45.

76. Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA. Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 1996;124:176-187.

77. Meltzer HY, Maes M, Lee MA. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Psychopharmacology 1993;112:S95–S104.

78. Meltzer HY, Maes M. Pindolol pretreatment blocks stimulation by metachlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Res 1995;58:89-98.

79. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238–246.

80. Mendels J. The effect of methysergide (a serotonin agent) on schizophrenia: a preliminary report. Br J Psychiatry 1967;124:157–160.

81. Mita T, Hanada S, Nishino N, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986;21:1407–1414.

82. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990;54:1755-1760.

83. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320–327.

84. Nash JF, Meltzer HY. Neuroendocrine studies in psychiatric disorders: the role of serotonin. In: Brown S-L, van Praag HM, eds. The role of serotonin in psychiatric disorders. New York: Brunner/Mazel 1991;57–90.

85. Nasrallah HA, Smith RE, Dunner FJ, McCalley-Whitter M. Serotonin precursor effect in tardive dyskinesia. Psychopharmacology 1982;11:234–235.

86. Nedergaard S, Bolam JP, Greenfield SA. Facilitation of dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 1988;333:174–177.

87. Nisstriandt H, Waters N, Hyarth S. The influence of serotonergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. N-S Arch Pharmacol 1992;346:12–19.

88. Nothen NM, Ritschel M, Erdmann J, et al. Genetic variation of the 5-HT2a receptor and response to clozapine. Lancet 1995;346:908.

89. Ohlund LS, Lindstrom LH, Ohman A. Electrodermal orienting response and central nervous system dopamine and serotonin activity in schizophrenia. J Nerv Mental Dis 1992;180:304–313.

90. Ostrowitzki S, Rao ML, Redei J, Andres AH. Concurrence of cortex and platelet serotonin 2 receptor binding characteristics in the individual and the putative regulation by serotonin. J Neural Transm 1993;93;27-35.

91. Pehek EA, Meltzer HY, Yamamoto BK. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 1993;240:107-110.

92. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psych 1992;49:345–353.

93. Pilowsky LS, costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. Br J Psychiatry 1994;164:16-26.

94. Potkin SG, Weinberger DR, Linoila M, Wyatt RJ. Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. Am J Psychiatry 1983;140:21–25.

95. Price LH, Charney DS, Delgado PL, et al. Clinical studies of 5-HT function using i.v. L-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:459–472.

96. Reynolds GP, Rossor M, Iversen LL. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Trans 1983;18[Suppl]:273–277.

97. Rogue A, Rogue P. Mianserin in the management of schizophrenia. In: Schizophrenia 1992: an international conference. 1992:135.

98. Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents with transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 1992;260:1361–1365.

99. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine6 (5-HT6) and 5-hydroxytryptamine7 (5-HT7) receptors. J Pharmacol Exp Ther 1994;268:1403–1410.

100. Roth BL, Hamblin MW, Ciaranello RD. Regulation of 5-HT2 and 5-HT1C serotonin receptor levels: methodology and mechanisms. Neuropsychopharmacology 1990;3:427–433.

101. Roth BL, Hamblin MW, Ciarnello RD. Developmental regulation of 5-HT2 and 5-HT1C mRNA and receptor levels. Develop Brain Res 1991;58:51–58.

102. Roy A, Ninan P, Mazonson A, et al. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychol Med 1985;15:335–340.

103. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 1995;56:2209-2222.

104. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.

105. Sharma RP, Shapiro LE. The 5-HT1A receptor system: Possible implications for schizophrenic negative symptomatology. Psychiatr Ann 1996;26:88-92.

106. Seeman P, Corbett, Van Tol HHM. Atypical neuroleptics have low affinity for dopamine D2 receptors. Neuropsychopharmacol 1997;16:93-110.

107. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neutrons. Science 1975; 188:1217-1219.

108. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-HT7 serotonin receptor subtype. J Biol Clin 1993;268:18200–18204.

109. Silver H, Blacker M, Weller MPI, Lerer B. Treatment of chronic schizophrenia with cyproheptadine. A double-blind placebo controlled study. Biol Psychiatry 1991;30:523-525.

110. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double blind, placebo study. Biol Psychiatry 1991;38:698-704.

111. Simpson MDC, Lubman DI, Slater P, Deakin JFW. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 1996;39:919-928.

112. Skorzewsak A, Lal S. Methysergide-induced psychosis: case report with long-term follow-up. Neuropsychobiology 1989;22:125–127.

113. Soper HV, Elliott RO, Rejzer AA, Marshall BD. Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenic patients. J Clin Psychopharmacol 1990;10:168–175.

114. Sorensen SM, Kehne JH, Fadayl EM, et al. Characterization of the 5-HT2 antagonists MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993;266:684–691.

115. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993;266:1374–1384.

116. Sumoyshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 1996;708:209-214.

117. Svensson TH, Mathe JM, Andersson JL, et al. Mode of action of atypical neuroleptics in relatin to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-andrenoceptor antagonism. J Clin Psychopharmacol 1995;15:11S-18S.

118. Szara S. Hallucinogenic amines and schizophrenia. New York: Pergamon Press; 1967.

119. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-143.

120. Szymanski S, Lieberman J, Pollack S, et al. The dopamine-serotonin relationship in clozapine response. Psychopharmacology 1993; 112,S85–S89.

121. Trent F, Tepper JM. Dosal raphe stimulation modifies striatal-evoked antidromic invasion of nigral dopaminergic neurons in vivo. Exp Brain Res 1991;84:620–630.

122. Tuckwell HC, Koziol JA. On the concentration of 5-hydroxyindoleacetic acid in schizophrenia: A meta-analysis. Psychiatry Res 1996;59:239-244.

123. Ugedo L, Genhoff J, Svensson TH. Ritanserin, a 5-HT2 receptor antagonists, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989;98:45-50.

124. Van Praag HM. CSF 5HIAA and suicide in non-depressed schizophrenics. Lancet II:1983;977–978.

125. Wadenberg ML. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm 1992;89:49–59.

126. Weinberger DR. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-669.

127. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609–615.

128. Whitaker PM, Crow TJ, Ferrer IN. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psych 1981;38:278–280.

129. Williams J, Davies JA. The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra. J Pharm Pharmacol 1983;35:734–737.

130. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T 102C polymorphism of the 5-hydroxytryptophan 2A receptor gene. Lancet 1996;347:1294-1296.

131. Wooley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954;40:228–231.